Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Sidney Kimmel Comprehensive Cancer Center, Asan Medical Center, Universitair Ziekenhuis Leuven, KU Leuven, Tel Aviv Sourasky Medical Center, National Center for Tumor Diseases, Saitama Cancer Center, Royal Brisbane and Women's Hospital, Indiana University Health, Indiana University – Purdue University Indianapolis, McGill University Health Centre, National Cancer Center Hospital East, Centre Hospitalier Universitaire de Toulouse, Aichi Cancer Center, Vall d'Hebron Institute of Oncology, Krankenhaus Nordwest, Roswell Park Comprehensive Cancer Center, Providence Portland Medical Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Memorial Sloan Kettering Cancer Center, Sorbonne Université